S100A4 Antibody (YA5318)
(Synonyms: 18A2; 42A; calcium Placental protein; Calvasculin; CAPL; Fibroblast specific protein 1; Fibroblast specific protein; FSP1; Leukemia multidrug resistance associated protein; Malignant transformation suppression 1; Metastasin; MTS1; OTTHUMP00000015467; OTTHUMP00000015468; P9KA; PEL98; Placental calcium-binding protein; Protein Mts1; Protein S100 A4; Protein S100-A4; S100 calcium binding protein A4; calcium protein, calvasculin, metastasin, murine placental homolog; S100 calcium binding protein A4; S100 calcium-binding protein A4; S100a4; S10A4_HUMAN.)S100A4 Antibody (YA5318) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to S100A4.
-
Host:
Mouse
-
Application:
WB
-
Reactivity :
Human
-
Formulation:
Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
|---|---|
| Dilution Ratio | 1:500-1:1000 |
Product Details
S100A4 Antibody (YA5318) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to S100A4.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 12 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Recombinant human S100A4 protein.
affinity chromatography.
Non-conjugated
Unmodified
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
S100A4 is a member of the S100 family of low molecular weight calcium-binding proteins that modulate intracellular and extracellular signaling processes[1]. Mechanistically, S100A4 interacts with cytoskeletal elements, including actin and non-muscle myosin, to regulate cell motility, migration, and invasion, contributing to tissue remodeling and metastasis[2][3]. In disease models, S100A4 expression is elevated in fibrotic tissues, various cancers, and neurological disorders, where it promotes progression by activating RAGE-mediated pathways and influencing epithelial-mesenchymal transition[1][3]. Compared with related isoforms such as S100A1 and S100B, S100A4 exhibits lower basal expression in normal tissues but higher inducibility under pathological stress, indicating isoform-specific regulation[1][4]. Experimental inhibition of S100A4 using small-molecule antagonists or peptide-based inhibitors suppresses motility and metastasis in vitro and in vivo, highlighting its utility as a target for translational research[1][5]. For experimental applications, S100A4 can serve as a biomarker for tumor aggressiveness and as a modulator of fibroblast and immune cell function in tissue remodeling assays[1][2]. Collectively, S100A4 represents a distinct functional isoform within the S100 family, integrating calcium-dependent signaling with cytoskeletal regulation and disease pathogenesis.
-
Subcellular Localization
Secreted; Nucleus; Cytoplasm
-
Expression
Tissue_specificity:general expression -
Subunit
Homodimer. Interacts with PPFIBP1 in a calcium-dependent mode (PubMed:11836260). Interacts with PGLYRP1; this complex acts as a chemoattractant that promotes lymphocyte movement (PubMed:26654597, PubMed:30713770). Interacts with MYH9; this interaction increases cell motility (PubMed:16707441). Interacts with Annexin 2/ANXA2 (PubMed:28669632). Interacts with TP53; this interaction promotes TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CCR5 (PubMed:30713770). Interacts with FCGR3A; this interaction inhibits PKC-dependent phosphorylation of FCGR3A
-
SwissProt ID
-
Synonyms
18A2; 42A; calcium Placental protein; Calvasculin; CAPL; Fibroblast specific protein 1; Fibroblast specific protein; FSP1; Leukemia multidrug resistance associated protein; Malignant transformation suppression 1; Metastasin; MTS1; OTTHUMP00000015467; OTTHUMP00000015468; P9KA; PEL98; Placental calcium-binding protein; Protein Mts1; Protein S100 A4; Protein S100-A4; S100 calcium binding protein A4; calcium protein, calvasculin, metastasin, murine placental homolog; S100 calcium binding protein A4; S100 calcium-binding protein A4; S100a4; S10A4_HUMAN.
Documentation
[1]. Delangre E, et al. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. Int J Mol Sci. 2022 Sep 20;23(19):11030. [Content Brief]
[2]. Kraus C, et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol. 2009 Oct;47(4):445-55. [Content Brief]
[3]. Wilder PT, et al. Targeting S100 Calcium-Binding Proteins with Small Molecule Inhibitors. Methods Mol Biol. 2019;1929:291-310. [Content Brief]
[5]. Martínez-Aguilar J, et al. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer. 2015;15:199. [Content Brief]
Powered by Bioz
